Efficacy and safety of upadacitinib for Crohn’s disease in patients in East Asia: a post hoc analysis of randomized phase 3 studies - Quiz - MDSpire
Coming Soon: Introducing MDSpire News. Learn more
Conexiant’s news site is now MDSpire News. Learn more

Assessment of the Safety and Efficacy of Upadacitinib in Treating Crohn’s Disease Among East Asian Patients: A Post Hoc Evaluation of Phase 3 Randomized Trials

  • By

  • Minhu Chen

  • Xiang Gao

  • Kenji Watanabe

  • Toshimitsu Fujii

  • Jae Hee Cheon

  • Shu-Chen Wei

  • Yuh-Ying Yeh

  • Yasuko Ishikawa

  • Patrick M. Hecht

  • Andrew Garrison

  • Irina Fish

  • Fernando Aponte

  • Silvio Danese

  • Hiroshi Nakase

  • August 30, 2026

Share

Original Source(s)

Efficacy and safety of upadacitinib for Crohn’s disease in patients in East Asia: a post hoc analysis of randomized phase 3 studies

  • by Minhu Chen, Xiang Gao, Kenji Watanabe, Toshimitsu Fujii, Jae Hee Cheon, Shu-Chen Wei, Yuh-Ying Yeh, Yasuko Ishikawa, Patrick M. Hecht, Andrew Garrison, Irina Fish, Fernando Aponte, Silvio Danese, Hiroshi Nakase

  • August 30, 2026

Related Content

Prenatal Exposure to Acid-Suppressive Medications and Incident Risk of Inflammatory Bowel Disease in Children

Diagnostic performance of fecal eosinophil-derived neurotoxin and lipocalin-2 in pediatric inflammatory bowel disease

Uptake and Use of Biologic Therapies in Paediatric Immune-Mediated Inflammatory Diseases: An Australian Population-Based Study